ABSTRACT
Resumo Fundamento O infarto do miocárdio com artérias coronárias não obstrutivas (MINOCA) constitui um subconjunto significativo de infartos agudos do miocárdio (IAM) com marcadores prognósticos incertos. A avaliação precoce do risco é crucial para identificar pacientes MINOCA em risco de resultados adversos. Objetivos Este estudo teve como objetivo avaliar a capacidade preditiva do escore PRECISE-DAPT na avaliação do prognóstico de curto e longo prazo em pacientes MINOCA que apresentam infarto do miocárdio sem supradesnivelamento do segmento ST (IAMSSST) ou com supradesnivelamento do segmento ST (IAMCSST). Métodos Entre 741 pacientes MINOCA, o escore PRECISE-DAPT foi calculado para analisar sua associação com eventos cardiovasculares adversos maiores (MACE) intra-hospitalares e de acompanhamento. Os parâmetros que apresentaram significância nos grupos MACEM (+) foram submetidos à análise estatística: regressão logística univariada para eventos intra-hospitalares e regressão univariada de Cox para eventos de seguimento. Para significância estatística, foi adotado nível pré-definido de α = 0,05. Os parâmetros que demonstraram significância foram submetidos à regressão logística múltipla para eventos intra-hospitalares e à regressão multivariada de Cox para eventos de seguimento. Resultados Os MACE intra-hospitalares ocorreram em 4,1% dos pacientes, enquanto 58% apresentaram MACE no acompanhamento. Os níveis de hemoglobina e o escore PRECISE-DAPT foram identificados como parâmetros independentes para MACE intra-hospitalar. Além disso, a fração de ejeção (FE%) e o escore PRECISE-DAPT surgiram como preditores independentes de MACE no acompanhamento. Conclusões O estudo revelou que um escore PRECISE-DAPT mais alto foi significativamente associada a riscos aumentados de eventos cardiovasculares adversos maiores tanto intra-hospitalares quanto de longo prazo em pacientes MINOCA que apresentam síndrome coronariana aguda (SCA), ressaltando o potencial do escore na estratificação de risco para esta coorte de pacientes.
Abstract Background Myocardial infarction with non-obstructive coronary arteries (MINOCA) constitutes a significant subset of acute myocardial infarctions (AMI) with uncertain prognostic markers. Early risk assessment is crucial to identify MINOCA patients at risk of adverse outcomes. Objectives This study aimed to evaluate the predictive capacity of the PRECISE-DAPT score in assessing short- and long-term prognoses in MINOCA patients presenting with ST-segment elevation myocardial infarction (STEMI) or non-ST-elevation myocardial infarction (NSTEMI). Methods Among 741 MINOCA patients, the PRECISE-DAPT score was computed to analyze its association with in-hospital and follow-up major adverse cardiovascular events (MACE). Parameters showing significance in MACE (+) groups underwent statistical analysis: univariate logistic regression for in-hospital events and univariate Cox regression for follow-up events. For statistical significance, a predefined level of α = 0.05 was adopted. Parameters demonstrating significance proceeded to multiple logistic regression for in-hospital events and multivariate Cox regression for follow-up events. Results In-hospital MACE occurred in 4.1% of patients, while 58% experienced follow-up MACE. Hemoglobin levels and the PRECISE-DAPT Score were identified as independent parameters for in-hospital MACE. Furthermore, ejection fraction (EF%) and the PRECISE-DAPT Score emerged as independent predictors of follow-up MACE. Conclusions The study revealed that a higher PRECISE-DAPT score was significantly associated with increased risks of both in-hospital and long-term major adverse cardiovascular events in MINOCA patients presenting with acute coronary syndrome (ACS), underscoring the score's potential in risk stratification for this patient cohort.
ABSTRACT
BACKGROUND/INTRODUCTION: Heart failure patients with reduced ejection fraction are at high risk for ventricular arrhythmias and sudden cardiac death. Ivabradine, a specific inhibitor of the If current in the sinoatrial node, provides heart rate reduction in sinus rhythm and angina control in chronic coronary syndromes. OBJECTIVE: The effect of ivabradine on ventricular arrhythmias in heart failure patients with reduced ejection fraction patients has not been fully elucidated. The aim of this study was to investigate the effect of ivabradine use on life-threatening arrhythmias and long-term mortality in heart failure patients with reduced ejection fraction patients. METHODS: In this retrospective study, 1,639 patients with heart failure patients with reduced ejection fraction were included. Patients were divided into two groups: ivabradine users and nonusers. Patients presenting with ventricular tachycardia, the presence of ventricular extrasystole, and ventricular tachycardia in 24-h rhythm monitoring, appropriate implantable cardioverter-defibrillator shocks, and long-term mortality outcomes were evaluated according to ivabradine use. RESULTS: After adjustment for all possible variables, admission with ventricular tachycardia was three times higher in ivabradine nonusers (95% confidence interval 1.5-10.2). The presence of premature ventricular contractions and ventricular tachycardias in 24-h rhythm Holter monitoring was notably higher in ivabradine nonusers. According to the adjusted model for all variables, 4.1 times more appropriate implantable cardioverter-defibrillator shocks were observed in the ivabradine nonusers than the users (95%CI 1.8-9.6). Long-term mortality did not differ between these groups after adjustment for all covariates. CONCLUSION: The use of ivabradine reduced the appropriate implantable cardioverter-defibrillator discharge in heart failure patients with reduced ejection fraction patients. Ivabradine has potential in the treatment of ventricular arrhythmias in heart failure patients with reduced ejection fraction patients.
Subject(s)
Heart Failure , Tachycardia, Ventricular , Ventricular Dysfunction, Left , Humans , Ivabradine/therapeutic use , Ivabradine/pharmacology , Stroke Volume/physiology , Retrospective Studies , Arrhythmias, Cardiac/drug therapy , Heart Failure/complications , Heart Failure/drug therapy , Tachycardia, Ventricular/drug therapyABSTRACT
SUMMARY BACKGROUND/INTRODUCTION: Heart failure patients with reduced ejection fraction are at high risk for ventricular arrhythmias and sudden cardiac death. Ivabradine, a specific inhibitor of the If current in the sinoatrial node, provides heart rate reduction in sinus rhythm and angina control in chronic coronary syndromes. OBJECTIVE: The effect of ivabradine on ventricular arrhythmias in heart failure patients with reduced ejection fraction patients has not been fully elucidated. The aim of this study was to investigate the effect of ivabradine use on life-threatening arrhythmias and long-term mortality in heart failure patients with reduced ejection fraction patients. METHODS: In this retrospective study, 1,639 patients with heart failure patients with reduced ejection fraction were included. Patients were divided into two groups: ivabradine users and nonusers. Patients presenting with ventricular tachycardia, the presence of ventricular extrasystole, and ventricular tachycardia in 24-h rhythm monitoring, appropriate implantable cardioverter-defibrillator shocks, and long-term mortality outcomes were evaluated according to ivabradine use. RESULTS: After adjustment for all possible variables, admission with ventricular tachycardia was three times higher in ivabradine nonusers (95% confidence interval 1.5-10.2). The presence of premature ventricular contractions and ventricular tachycardias in 24-h rhythm Holter monitoring was notably higher in ivabradine nonusers. According to the adjusted model for all variables, 4.1 times more appropriate implantable cardioverter-defibrillator shocks were observed in the ivabradine nonusers than the users (95%CI 1.8-9.6). Long-term mortality did not differ between these groups after adjustment for all covariates. CONCLUSION: The use of ivabradine reduced the appropriate implantable cardioverter-defibrillator discharge in heart failure patients with reduced ejection fraction patients. Ivabradine has potential in the treatment of ventricular arrhythmias in heart failure patients with reduced ejection fraction patients.